Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report

BACKGROUND: Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC). Giving the rapid pace of drug discovery and development in this area, reporting of adverse effects of ALK inhibitors is crucial. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Guisier, F., Piton, N., Bellefleur, M., Delberghe, N., Avenel, G., Angot, E., Vittecoq, O., Ould-Slimane, M., Morisse-Pradier, H., Salaun, M., Thiberville, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945627/
https://www.ncbi.nlm.nih.gov/pubmed/31906956
http://dx.doi.org/10.1186/s12885-019-6486-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945627/
https://www.ncbi.nlm.nih.gov/pubmed/31906956
http://dx.doi.org/10.1186/s12885-019-6486-3

Ejemplares similares